TacticScaleWhat Keymed Biosciences Does & How It Makes Money (2162.HK)
Updated October 2026 · reflects Keymed Biosciences's latest reported financials
Chinese biotech developing antibody drugs for immune diseases and cancer. It earns revenue from selling its commercial drug Kangyueda and from out-licensing pipeline assets to partners such as Belenos, Platina, Prolium and Timberlyne, plus partnerships like CMG901/AZD0901.
How Keymed Biosciences makes money
It earns revenue from selling its commercial drug Kangyueda and from out-licensing pipeline assets to partners such as Belenos, Platina, Prolium and Timberlyne, plus partnerships like CMG901/AZD0901.
What Keymed Biosciences does
Keymed Biosciences, founded in 2016 and headquartered in Chengdu, is a biotechnology company developing biological therapies for autoimmune diseases and cancer, with operations in Mainland China, the US and the UK. Its most advanced product, Kangyueda, targets moderate-to-severe atopic dermatitis in adults, chronic rhinosinusitis with nasal polyps and seasonal allergic rhinitis. Its pipeline spans antibody drug conjugates (CMG901/AZD0901, CM518D1), bispecific antibodies (CM512, CM336, CM350, CM355) and antibodies for immune thrombocytopenia (CM313) and Alzheimer's disease (CM383, CM559), most of them in Phase I–II trials. Keymed also out-licenses assets to partners including Belenos, Platina, Prolium and Timberlyne Therapeutics.
Products & services
- Kangyueda
- CMG901/AZD0901 (ADC)
- CM512 (TSLP x IL-13 bispecific)
- CM336 (BCMA x CD3 bispecific)
- CM313
- CM383 (Aβ protofibril antibody)
What is Keymed Biosciences worth?
A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.
We show a fair value only when the method is trustworthy. See Keymed Biosciences on TacticScale →
Related companies
Bio-Thera Solutions (688177.SS) · Biocytogen Pharmaceuticals (Beijing) (2315.HK) · Xencor (XNCR) · RemeGen (688331.SS)